A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV‐related HCC treated with sorafenib

Yu, Yang; Wen, Feng; Li, Jianliang; Zhang, Pengfei; Yan, Wenhui; Hao, Ping; Xia, Feng; Bi, Feng; Li, Qiu

doi:10.1111/liv.12805

Cited by 39 publications

(43 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The association between HBV viral load and mutation of nt1753 was still unclear. Moreover, many studies have demonstrated that a high viral load was an adverse prognostic factor for survival of HBV‐related HCC patients . Then the association of T1753C mutation and HBV‐related HCC patients’ survival were still controversial.…”

Section: Discussionmentioning

confidence: 99%

HBV mutations in EnhII/BCP/PC region contribute to the prognosis of hepatocellular carcinoma

Tian

Meng

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

Background Accompanied by HBV infection, HBV mutations gradually occur because HBV polymerase appears proofread deficiencies. In our previous study, we have identified that EnhII/BCP/PC mutations and genotype C of HBV DNA were associated with hepatocellular carcinoma (HCC) risk. In this study, we extend our research to explore HCC prognosis associated genotype and mutations in EnhII/BCP/PC regions. Methods We designed a case‐cohort study of 331 HCC patients to evaluate the effects of the HBV genotypes and mutations on HCC survival. Log‐rank test and Cox proportional hazard models were used for the analyses. Results Results showed that genotype C, which was more frequent in HBV‐related HCC (77.4%), presented a negative signal with HCC survival. Interestingly, we detected a significant association between EnhII/BCP/PC mutation nt1753 and HCC prognosis (Log‐rank P = 0.034). Subgroup analysis revealed that this risk effect was more pronounced in non‐B genotype (P = 0.090 for heterogeneity test). We also detected a borderline multiplicative interaction between genotypes of nt1753 and HBV genotype on HCC survival (P for interaction = 0.069). Conclusions These findings indicated that, in Chinese population, nt1753 in EnhII/BCP/PC region might be a novel marker for HCC prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

HBV mutations in EnhII/BCP/PC region contribute to the prognosis of hepatocellular carcinoma

Tian

Meng

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Interestingly, sorafenib has an additional inhibitory effect on multiple steps of HCV replication [ 135 , 136 ]. In HBV-related HCC treated with sorafenib, high HBV load was associated with poor prognosis unless an anti-viral therapy was added to the therapy [ 137 ].…”

Section: Therapeutic Applications Of Targeting Vegf In Viral Diseamentioning

confidence: 99%

VEGF Upregulation in Viral Infections and Its Possible Therapeutic Implications

Alkharsah

2018

IJMS

View full text Add to dashboard Cite

Several viruses are recognized as the direct or indirect causative agents of human tumors and other severe human diseases. Vascular endothelial growth factor (VEGF) is identified as a principal proangiogenic factor that enhances the production of new blood vessels from existing vascular network. Therefore, oncogenic viruses such as Kaposi’s sarcoma herpesvirus (KSHV) and Epstein-Barr virus (EBV) and non-oncogenic viruses such as herpes simplex virus (HSV-1) and dengue virus, which lack their own angiogenic factors, rely on the recruitment of cellular genes for angiogenesis in tumor progression or disease pathogenesis. This review summarizes how human viruses exploit the cellular signaling machinery to upregulate the expression of VEGF and benefit from its physiological functions for their own pathogenesis. Understanding the interplay between viruses and VEGF upregulation will pave the way to design targeted and effective therapeutic approaches for viral oncogenesis and severe diseases.

show abstract

“…Likewise, anti‐viral therapy after radiofrequency ablation is associated with decreased HCC recurrence . The data on anti‐viral therapy in patients treated with palliative therapy, including transarterial chemoembolisation (TACE) and sorafenib are more limited, but in the case of TACE, a randomised controlled trial demonstrated that anti‐viral therapy increases survival …”

Section: Introductionmentioning

confidence: 99%

Anti‐viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus‐related hepatocellular carcinoma: real‐world east and west experience

Chen

Yeh

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV‐related HCC treated with sorafenib

Abstract: In patients with advanced HBV-related HCC treated with sorafenib, a high baseline HBV load was an adverse prognostic factor for survival. However, survival was significantly improved with the use of antiviral therapy.

Cited by 39 publications

References 34 publications

HBV mutations in EnhII/BCP/PC region contribute to the prognosis of hepatocellular carcinoma

HBV mutations in EnhII/BCP/PC region contribute to the prognosis of hepatocellular carcinoma

VEGF Upregulation in Viral Infections and Its Possible Therapeutic Implications

Anti‐viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus‐related hepatocellular carcinoma: real‐world east and west experience

Contact Info

Product

Resources

About